Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont/Nova

Executive Summary

DuPont Medical Products signs five-year agreement with receptor R&D firm Nova Pharmaceutical covering development and marketing of products for the molecular screening of chemical compounds for biological activity. Using its NovaScreen technology, Nova will develop and test products for DuPont, which will receive manufacturing and marketing rights. The first products will be kits for performing receptor binding assays. Nova also has drug screening pacts with Sterling and NIH as well as with several Japanese firms.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel